Article Text
Abstract
Background: Many people participating in dementia research may lack capacity to give informed consent and the relationship between cognitive function and capacity remains unclear. Recent changes in the law reinforce the need for robust and reproducible methods of assessing capacity when recruiting people for research.
Aims: To identify numbers of capacitous participants in a pragmatic randomised trial of dementia treatment; to assess characteristics associated with capacity; to describe a legally acceptable consent process for research.
Methods: As part of a pragmatic randomised controlled trial of Ginkgo biloba for mild-moderate dementia, we used a consenting algorithm that met the requirements of existing case law and the exigencies of the new Mental Capacity Act. We decided who had capacity to give informed consent for participation in the trial using this algorithm and sought predictors of capacity.
Results: Most participants (76%) with mild-moderate dementia in this trial were unable to give informed consent according to the legal criteria. When adjusted for confounding, the Mini Mental State examination did not predict the presence of capacity.
Conclusion: Cognitive testing alone is insufficient to assess the presence of capacity. Researchers and clinicians need to be aware of the challenging processes regarding capacity assessment. We outline a procedure which we believe meets the ethical and legal requirements.
Statistics from Altmetric.com
Footnotes
Funding: The original study is funded by the Alzheimer’s society and has the approval of South-West Multi Research Ethics Committee
Competing interests: None.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- Linking the Mini-Mental State Examination, the Alzheimer ’s Disease Assessment Scale – Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil
- Profile of cognitive impairment in dementia associated with Parkinson ’s disease compared with Alzheimer ’s disease
- Insight, cognition and quality of life in Alzheimer 's disease
- ▼Donepezil for Alzheimer 's disease
- Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial
- The ADAS - cog in Alzheimer 's disease clinical trials: psychometric evaluation of the sum and its parts
- Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression
- Antipsychotics and cognitive decline in Alzheimer ’s disease: the LASER - Alzheimer ’s disease longitudinal study
- What is the clinically relevant change on the ADAS - Cog
- Dynamics of brain structure and cognitive function in the Alzheimer 's disease neuroimaging initiative